Catamenial Epilepsy Clinical Trial
Pilot Study of Add-On Fycompa (Perampanel)Treatment for Catamenial Epilepsy
The purpose of the proposed investigation is to carry out a pilot study of add-on perampanel (Fycompa) in women with perimenstural (C1) catamenial epilepsy. Perampanel, a noncompetitive AMPA receptor antagonist, is uniquely positioned to decrease progesterone receptor mediated excitotoxicity. This mechanism of action would allow a novel use of perampanel as an effective treatment of C1 catamenial epilepsy.
|Source||University of Florida|
|Start date||March 9, 2022|
|Completion date||January 2023|